Coronavirus: Llamas offer hope in fight against the outbreak

Camelids produce antibodies that have been found to neutralise Covid-19

Jillian Kramer
Thursday 07 May 2020 13:31
Comments
Llamas offer hope in fight against the outbreak

Winter is a four-year-old chocolate-coloured llama with spindly legs, ever-so-slightly askew ears and envy-inducing eyelashes. Some scientists hope she might be an important figure in the fight against the coronavirus.

It is not a superpowered camelid. Winter was simply the lucky llama chosen by researchers in Belgium, where she lives, to participate in a series of virus studies involving both Sars and Mers. Finding that its antibodies staved off those infections, the scientists posited that those same antibodies could also neutralise the new virus that causes Covid-19. They were right and published their results Tuesday in the journal Cell.

Scientists have long turned to llamas for antibody research. In the past decade, for example, scientists have used llamas’ antibodies in HIV and influenza research, finding promising therapies for both viruses.

Humans produce only one kind of antibody, made of two types of protein chains — heavy and light — that together form a Y shape. Heavy-chain proteins span the entire Y, while light-chain proteins touch only the Y’s arms. Llamas, on the other hand, produce two types of antibodies.

One of those antibodies is similar in size and constitution to human antibodies. But the other is much smaller; it’s only about 25 per cent the size of human antibodies. The llama’s antibody still forms a Y, but its arms are much shorter because it doesn’t have any light-chain proteins.

This more diminutive antibody can access tinier pockets and crevices on spike proteins — the proteins that allow viruses like the coronavirus to break into host cells and infect us — that human antibodies cannot. That can make it more effective in neutralising viruses.

Llamas’ antibodies are also easily manipulated, said Dr Xavier Saelens, a molecular virologist at Ghent University in Belgium and an author of the new study. They can be linked or fused with other antibodies, including human antibodies, and remain stable despite those manipulations.

This antibody is a genetic characteristic llamas share with all camelids, the family of mammals that also includes alpacas, guanacos and dromedaries.

Sharks have these smaller antibodies, too, but they “are not a great experimental model, and are a lot less cuddly than llamas”, said Daniel Wrapp, a graduate student affiliated with the University of Texas at Austin and Dartmouth College, and a co-author of the new research. Dr Saelens said that llamas are domesticated, easy to handle and less stubborn than many of their camelid cousins, although, “if they don’t like you, they’ll spit.”

In 2016, Dr Saelens, Mr Wrapp and Dr Jason McLellan, a structural virologist at the University of Texas at Austin, and other researchers looked to llamas — and, specifically, Winter — to find a smaller llama antibody “that could broadly neutralise many different types of coronavirus”, Dr McLellan said.

They injected Winter with spike proteins from the virus that caused the 2002-03 Sars epidemic as well as Mers, then tested a sample of its blood. And while they could not isolate a single llama antibody that worked against both viruses, they found two potent antibodies that each fought separately against Mers and Sars.

The researchers were writing up their findings when the new coronavirus began to make headlines in January. They immediately realised that the smaller llama antibodies “that could neutralise Sars would very likely also recognise the Covid-19 virus", Dr Saelens said.

It did, the researchers found, effectively inhibiting the coronavirus in cell cultures.

The researchers are hopeful the antibody can eventually be used as a prophylactic treatment, by injecting someone who is not yet infected to protect them from the virus, such as a health care worker. While the treatment’s protection would be immediate, its effects wouldn’t be permanent, lasting only a month or two without additional injections.

This proactive approach is at least several months away, but the researchers are moving towards clinical trials. Additional studies may also be needed to verify the safety of injecting a llama’s antibodies into human patients.

“There is still a lot of work to do to try to bring this into the clinic,” Dr Saelens said. “If it works, llama Winter deserves a statue.”

The New York Times

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in